 | • レポートコード：MRC2303E036 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、241ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療機器 |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、2021年に122.8億ドルであった世界の神経保護市場規模が、2022年に134.5億ドルに達し、2027年には214.7億ドルまで年平均9.75%で成長すると予測しています。当調査レポートでは、神経保護の世界市場について総合的に調査・分析を行い、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別分析（アポトーシス阻害剤、遊離型抗炎症剤、グルタミン酸拮抗薬、金属イオンキレート剤、その他）、治療別分析（アルツハイマー病、筋萎縮性側索硬化症、脳損傷、ハンチントン病、その他）、用途別分析（予防、治療）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況などの項目を掲載しています。なお、当書に掲載されている企業情報には、AbbVie Inc.、Allergan plc、Allon therapeutics, Inc.、AstraZeneca plc、Astrocyte Pharmaceuticals, Inc.、Bayer Healthcare, Eisai Inc.、Bio Vision Inc.、Biogen Inc.、Bionure Inc.、Ceregene, BHRPharma LLC、Daiichi Sankyo Company、Dr. Reddy’s Laboratories Ltd.、Eisai Inc.、Eli Lilly and Companyなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の神経保護市場規模：製品別 - アポトーシス阻害剤の市場規模 - 遊離型抗炎症剤の市場規模 - グルタミン酸拮抗薬の市場規模 - 金属イオンキレート剤の市場規模 - その他製品の市場規模 ・世界の神経保護市場規模：治療別 - アルツハイマー病治療の市場規模 - 筋萎縮性側索硬化症治療の市場規模 - 脳損傷治療の市場規模 - ハンチントン病治療の市場規模 - その他治療の市場規模 ・世界の神経保護市場規模：用途別 - 予防における市場規模 - 治療における市場規模 ・世界の神経保護市場規模：地域別 - 南北アメリカの神経保護市場規模 アメリカの神経保護市場規模 カナダの神経保護市場規模 ブラジルの神経保護市場規模 ... - アジア太平洋の神経保護市場規模 日本の神経保護市場規模 中国の神経保護市場規模 インドの神経保護市場規模 韓国の神経保護市場規模 台湾の神経保護市場規模 ... - ヨーロッパ/中東/アフリカの神経保護市場規模 イギリスの神経保護市場規模 ドイツの神経保護市場規模 インドの神経保護市場規模 フランスの神経保護市場規模 ロシアの神経保護市場規模 ... - その他地域の神経保護市場規模 ・競争状況 ・企業情報 |
The Global Neuroprotection Market size was estimated at USD 12.28 billion in 2021 and expected to reach USD 13.45 billion in 2022, and is projected to grow at a CAGR 9.75% to reach USD 21.47 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Neuroprotection to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Product, the market was studied across Apoptosis Inhibitors, Free Anti-Inflammatory Agents, Glutamate Antagonists, Metal Ion Chelators, Neurotrophic Factors, Radical Trapping Agents, and Stimulants.
Based on Treatment, the market was studied across Alzheimer’s disease, Amyotrophic lateral sclerosis, Brain injury, Huntington’s disease, Multiple sclerosis, Neuropathies, Ocular degeneration, and Parkinson’s disease.
Based on Application, the market was studied across Prevention and Treatment.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Neuroprotection market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Neuroprotection Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Neuroprotection Market, including AbbVie Inc., Allergan plc, Allon therapeutics, Inc., AstraZeneca plc, Astrocyte Pharmaceuticals, Inc., Bayer Healthcare, Eisai Inc., Bio Vision Inc., Biogen Inc., Bionure Inc., Ceregene, BHRPharma LLC, Daiichi Sankyo Company, Dr. Reddy’s Laboratories Ltd., Eisai Inc., Eli Lilly and Company, Genervon Biopharmaceuticals, GlaxoSmithKline Plc, Hoffmann-La Roche AG, Merck KGaA, Neuren Pharmaceuticals, NeuroVive Pharmaceutical, Novartis AG, Serono S.A., and Teva Pharmaceutical Industries Ltd..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Neuroprotection Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Neuroprotection Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Neuroprotection Market?
4. What is the competitive strategic window for opportunities in the Global Neuroprotection Market?
5. What are the technology trends and regulatory frameworks in the Global Neuroprotection Market?
6. What is the market share of the leading vendors in the Global Neuroprotection Market?
7. What modes and strategic moves are considered suitable for entering the Global Neuroprotection Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing drug development in the pharmaceutical and biotechnology owing to increasing occurrences of traumatic brain injury
5.1.1.2. Growing incidences of CNS diseases coupled with increasing awareness
5.1.1.3. Increased demand for target-specific drug treatment for neurodegenerative diseases along with favorable government regulations
5.1.1.4. Increasing healthcare infrastructure and increasing economic stability in developing economies, such as Latin America and Middle East & Africa
5.1.2. Restraints
5.1.2.1. Limited awareness in developing economies
5.1.3. Opportunities
5.1.3.1. New product launch, investment in R&D, and increasing drug discovery & product launch
5.1.3.2. Increasing use of neuroprotection in cosmetics
5.1.3.3. Increasing use of herbal extract free-radical trapping agents such as cannabidiol, Vitamins E and C
5.1.4. Challenges
5.1.4.1. High cost associated with neuro treatments
5.2. Cumulative Impact of COVID-19
6. Neuroprotection Market, by Product
6.1. Introduction
6.2. Apoptosis Inhibitors
6.3. Free Anti-Inflammatory Agents
6.4. Glutamate Antagonists
6.5. Metal Ion Chelators
6.6. Neurotrophic Factors
6.7. Radical Trapping Agents
6.8. Stimulants
7. Neuroprotection Market, by Treatment
7.1. Introduction
7.2. Alzheimer’s disease
7.3. Amyotrophic lateral sclerosis
7.4. Brain injury
7.5. Huntington’s disease
7.6. Multiple sclerosis
7.7. Neuropathies
7.8. Ocular degeneration
7.9. Parkinson’s disease
8. Neuroprotection Market, by Application
8.1. Introduction
8.2. Prevention
8.3. Treatment
9. Americas Neuroprotection Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Neuroprotection Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Neuroprotection Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. AbbVie Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Allergan plc
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Allon therapeutics, Inc.
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. AstraZeneca plc
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Astrocyte Pharmaceuticals, Inc.
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Bayer Healthcare, Eisai Inc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Bio Vision Inc.
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Biogen Inc.
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Bionure Inc.
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Ceregene, BHRPharma LLC
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Daiichi Sankyo Company
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Dr. Reddy’s Laboratories Ltd.
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Eisai Inc.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Eli Lilly and Company
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Genervon Biopharmaceuticals
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. GlaxoSmithKline Plc
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Hoffmann-La Roche AG
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Merck KGaA
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Neuren Pharmaceuticals
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. NeuroVive Pharmaceutical
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Novartis AG
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. Serono S.A.
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. Teva Pharmaceutical Industries Ltd.
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing